PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > Formulary Search > PAD Profile : Grazax (grass pollen) - Seasonal allergic hay fever (adults)
PAD Profile : Grazax (grass pollen) - Seasonal allergic hay fever (adults)
Brand Names Include :
Grass pollen extract
Traffic Light Status
Status 1 of 1.
Status :
Blue
Important
Formulations :
- Oral lyophilisates
Important Information :
RSFT Immunology only. Initiation and at least 1 month supply from specialist team before any request to transfer prescribing to primary care.
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Comments :
No comments returned.
Documents :
Guidelines
No guidelines returned.
Other Drugs
No drugs returned.
Other Indications
Additional Documents
No additional documents returned.
Committee Recommendations
Date
Committee Name
Narrative
06 November 2024
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)
The Surrey Heartlands Area Prescribing Committee agreed the traffic light status of this drug and indication as part of the Joint Formulary review.
27 March 2013
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
The KSS policy recommendations committee have reviewed their policy recommendation which was made initially in November 2007. The new recommendations were presented to the PCN members and the members noted that the wording of the statement has changed slightly but the recommendation remains the same, in that Grazax within its licensed indication may be considered as a second line treatment option for individuals with severe hay fever in specified patients
Associated BNF Codes
03. Respiratory System
03.04.02. Allergen immunotherapy